News by community
03.02.2020 Data published in npj Vaccines show Mymetics’ malaria CyRPA virosome vaccine elicits protective antibodies against Plasmodium falciparum parasites in preclinical in vitro and in vivo models
Epalinges, Switzerland, 3 February 2020 – Mymetics Corporation (OTCQB: MYMX), a pioneer in the research and development of virosome based vaccines and immunotherapies against human life disabling and infectious diseases, announced today that results from a study at the Swiss Tropical and Public Health Institute (Swiss TPH) were published on January 31, 2020 in the Nature Partner Journal (npj) Vaccines.
The publication with title “Vaccination with virosomally formulated recombinant CyRPA elicits protective antibodies against Plasmodium falciparum parasites in preclinical in vitro and in vivo models” shows that Mymetics’ virosome based vaccine elicited in mice and rabbits high titers of PfCyRPA-specific antibodies that bound to the blood-stage parasites. At a concentration of 10 mg/mL, purified total serum IgG from immunized rabbits inhibited parasite growth in vitro by about 80%. Furthermore, in a Plasmodium falciparum (Pf) infection mouse model, passive transfer of 10 mg of purified total IgG from PfCyRPA vaccinated rabbits reduced the in vivo parasite load by 77%.
The study shows that Mymetics influenza virosomes represent a suitable antigen delivery system for the induction of protective antibodies against the recombinant PfCyRPA, designating it as a highly suitable component for inclusion into a multivalent and multi-stage virosomal malaria vaccine.